RTOG 0625: A phase II study of bevacizumab with irinotecan in recurrent glioblastoma (GBM) Article

Gilbert, MR, Wang, M, Aldape, K et al. (2009). RTOG 0625: A phase II study of bevacizumab with irinotecan in recurrent glioblastoma (GBM) . JOURNAL OF CLINICAL ONCOLOGY, 27(15_suppl), 2011-2011. 10.1200/jco.2009.27.15_suppl.2011

cited authors

  • Gilbert, MR; Wang, M; Aldape, K; Lassman, A; Sorensen, AG; Mikkelson, T; Groves, M; Werner-Wasik, M; Regine, W; Mehta, M

authors

publication date

  • May 20, 2009

published in

keywords

  • 32 Biomedical and Clinical Sciences
  • 3211 Oncology and Carcinogenesis
  • 6 Evaluation of treatments and therapeutic interventions
  • 6.1 Pharmaceuticals
  • Brain Cancer
  • Brain Disorders
  • Cancer
  • Clinical Research
  • Clinical Trials and Supportive Activities
  • Hematology
  • Neurosciences
  • Orphan Drug
  • Patient Safety
  • Rare Diseases

Digital Object Identifier (DOI)

publisher

  • American Society of Clinical Oncology (ASCO)

start page

  • 2011

end page

  • 2011

volume

  • 27

issue

  • 15_suppl